Physician profile
Steven Rose
NPI 1174502652
$5,263.73
in general payments reported to CMS, 2019-2025
17 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $498 · 2021: $1,530 · 2022: $1,643 · 2023: $380 · 2024: $81.45 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511 · Education: $59.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.52 |
| Education | $59.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $3,995.26 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $343.03 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $135.64 | 2023-2025 | Syfovre |
| Genentech USA, INC. | $134.73 | 2019-2024 | Vabysmo |
| Eyepoint US, INC. | $127.81 | 2021-2023 | |
| Hoffmann-La Roche Limited | $125.00 | 2019 | |
| Boston Scientific Corporation | $118.52 | 2021 | |
| Bausch & Lomb Americas INC. | $88.95 | 2023 | Stellaris |
| Novartis Pharmaceuticals Corporation | $50.74 | 2019-2020 | |
| Abbvie INC. | $36.97 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.33 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $34.52 | 2025 | |
| Astellas Pharma US INC | $23.22 | 2025 | Izervay |
| Alimera Sciences, INC. | $14.01 | 2023 | Iluvien |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$75,365.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.